The focused pharmacokinetic properties including physicochemical characteristics and drug-likeness were predicted by using the web-based program SwissADME (SIB Swiss Institute of Bioinformatics, Écublens, Switzerland, www.swissadme.ch/, accessed on 30 October 2022) [56]. The screened compounds’ features were calculated compared to the known drug, osimertinib.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.